A groundbreaking study from The University of Queensland has uncovered a dangerous hidden feature in the venom of the Black Mamba, one of the world’s deadliest snakes.
Led by Professor Bryan Fry from UQ’s School of the Environment, researchers found that the venoms of three mamba species — the Black Mamba, Western Green Mamba, and Jameson’s Mamba — are far more neurologically complex than previously believed. This discovery sheds light on why antivenoms often fail to fully neutralize their deadly effects.
“These snakes aren’t just using one chemical weapon — they’re launching a coordinated attack at two different points in the nervous system,” Professor Fry explained.
Dual Attack on the Nervous System
Traditionally, most mamba bites were thought to cause flaccid paralysis, where muscles become limp due to postsynaptic neurotoxicity. Current antivenoms were designed to treat this effect.
But the new research revealed that the same venoms can also cause spastic paralysis — painful, uncontrollable muscle spasms — through presynaptic toxicity. Previously, scientists believed only the Eastern Green Mamba had this capability.
This explains a long-standing medical mystery: why some snakebite patients initially improve with antivenom, only to suddenly develop severe muscle spasms afterward.
“It’s like treating one disease and suddenly revealing another,” Fry said.
A Major Health Crisis in Africa
Mamba bites (Dendroaspis species) remain a significant public health threat in sub-Saharan Africa, responsible for an estimated 30,000 deaths each year.
PhD candidate Lee Jones, who carried out much of the experimental work, said the team was surprised by how antivenom sometimes “unmasked” the hidden presynaptic effects of the venom.
“We also found venom function varied by geographic location, especially among Black Mambas from Kenya and South Africa,” Jones explained. “This complicates treatment, because current antivenoms are not tailored to these regional differences.”
Towards Better Antivenoms
The study highlights the urgent need for new, specialized antivenoms that can counteract the full range of venom effects.
“This isn’t just academic curiosity — it’s a direct call to clinicians and antivenom manufacturers,” Fry emphasized. “By identifying the limitations of current treatments, we can improve snakebite care and ultimately save lives.”
The research, conducted in collaboration with the Monash Venom Group, was recently published in the journal Toxins.